Prognostic factors in COPD patients receiving long-term oxygen (LTO) therapy were recently analyzed, but very few studies considered the prognostic value of pulmonary artery pressure (PAP) in these patients. We investigated 84 patients who had undergone a right heart catheterization just before the onset of LTO. There were 75 men and 9 women, with a mean age of 63.0 ± 9.9 (SD) years, at the onset of LTO Eighty-four COPD patients were included in this study. There were 75 men and 9 women and the mean age at the onset of LTO was 63.0 + 9.9 (SD) years. The COPD was assessed on clinical grounds as history of productive cough with progressive exertional dyspnea and functional criteria: FEVI-vital capacity (VC) ratio of less than 60%, the total lung capacity (TLC) being more than 80% of the predicted value. Patients with an associated lung disease, eg, sequelae of pulmonary tuberculosis, pneumoconiosis, left heart diseases, marked obesity (body mass index more than 32), sleep apnea syndrome, or any other severe disease were excluded from the study. Therapy with LTO was initiated when the PaO2 value was persistently less than 55 mm Hg, patients being in a stable state of their disease, and in patients with PaO2 levels in the CHEST /
Prognostic factors in COPD patients receiving long-term oxygen (LTO) therapy were recently analyzed, but very few studies considered the prognostic value of pulmonary artery pressure (PAP) in these patients. We investigated 84 patients who had undergone a right heart catheterization just before the onset of LTO. There were 75 men and 9 women, with a mean age of 63.0 ± 9.9 (SD) years, at the onset of LTO. When PaO2 was persistently less than 55 mm Hg, LTO was initiated. This therapy was started in some patients with PaO2 in the range of 55 to 60 mm Hg if they had signs of cor pulmonale or a resting PAP of 25 mm Hg or greater at right heart catheterization. The daily duration of LTO was 16 h/d or more. Oxygen flow was adapted to achieve a PaO2 of 65 mm Hg or more. The patients were subdivided into subgroups according to the median value of age (cutoff value=63 years); vital capacity (2,250 mL); FEVI (800 mL); residual volume-total lung capacity ratio (58%); PaO2 value (52 mm Hg), PaCO2 level (45 mm Hg); and PAP (25 mm Hg). The cumulative 5-year survival rate was 48% for the group as a whole. Actuarial survival curves were plotted for the two subgroups of patients In patients with advanced COPD, FEV1 and arterial blood gas values (PaO2 and PaCO2) have been shown to be good indicators of prognosis.1-4 Further studies have indicated that pulmonary artery mean pressure (PAP) also had a good prognostic value: the higher the PAP, the shorter the life expectancy. [5] [6] [7] These studies concerned patients treated with conventional methods, not including long-term oxygen therapy (LTO). The well known Nocturnal Oxygen Therapy Trial (NOTT)8 and Medical Research Council (MRC) studies9 have showed that LTO, given 15 h or more per day, improved survival in hypoxemic COPD patients. LTO also has favorable effects on pulmonary hypertension since it stabilizes, and sometimes reverses, the progression of pulmonary hypertension. 10 range of 55 to 59 mm Hg, provided that they had signs of clinical cor pulmonale or a resting PAP of 25 mm Hg or more at right heart catheterization. The stability of hypoxemia before the onset of LTO was checked by repeated arterial blood gas measurements, the follow-up period being at least 1 month and 3 months whenever possible. '5 The daily duration of oxygen therapy was 16 h or more. Oxygen was provided in most of the patients by concentrators and was given by nasal prongs. The oxygen flow was adapted and checked at least once a year to achieve a PaO2 of 65 mm Hg or more. At the onset of LTO, the flow of 02 ranged between 1 and 3 L per minute. The patients included in that study were'regularly followed up (once every 2 to 3 months) at the outpatient clinic. Long-term therapy usually included inhaled 02-agonists, long-acting theophylline, and chest physiotherapy. Corticosteroids were prescribed only during acute episodes of respiratory failure.
Conventional spirography was performed with a 10-Ls closedcircuit water-sealed spirograph. Static lung volumes were measured by the closed-circuit helium dilution method. Reference values were those of the European Community.'6 Right heart catheterization was performed as previously described. 7 Briefly, the hemodynamic measurements were always done while the patient was in the supine position, in the morning, without premedication, 2 h after a light breakfast. For the purpose of this study, we used small-diameter Grandjean'8 catheters (4F, Plastimed; Saint-Leu-la-Foret, France). Arterial blood samples were obtained through a Cournand needle inserted in the humeral artery during right heart catheterization. In our department, right heart catheterization belongs to the investigations usually performed before the onset of LTO in hypoxemic COPD patients '9 after an informed consent has been obtained.
The LTO was initiated from 1976 to 1991 and the endpoint for the analysis of the data was February 1992. The duration of the follow-up ranged from 1 to 12 years. The possible influence of the following variables on mortality was assessed by statistical analysis, as discussed later: age at the onset of LTO, pulmonary volumes (VC, FEVI, FEVj/VC ratio; residual volume (RV)-TLC ratio), and arterial blood gases levels with patients breathing on ambient air (PaO2, PaCO2) and PAP.
Statistical Methods
Quantitative variables were compared by the Student's t test for unpaired data. Survival was calculated from the date of onset of LTO until death or up to the closing date of the study: February 28, 1992. Survival curves were established according to the actuarial method. Comparison between the survival curves defined for different groups was done by the log rank test. All quantitative variables were categorized before analysis and only clinically meaningful grouping was carried out. A multivariate analysis of survival using Cox's model of the proportional hazards regression was then performed. A stepwise regression using the maximum partial likelihood ratio method was used. All the variables without missing values were included in the stepwise procedure with a probability to enter set at 0.15 and a probability to remove value set at 0.10. Data were processed using the BMDP package from the University of California, Los Angeles.
RESULTS
The mean and median values of age, pulmonary volumes, arterial blood gas levels, and PAP of the 84 patients, at the onset of LTO, are given in Table 1 . Bronchial obstruction was generally severe with mean and median FEV1 values less than 900 mL. By definition, all the patients were markedly hypoxemic and the median PaO2 was 51.6 mm Hg. In 29 of 84 patients, the initial PaO2 value was less than 50 mm Hg. Half of the patients (44 of 84) were hypercapnic (-45 mm Hg), and the median PaCO2 was exactly 45 mm Hg. In only seven patients was the initial PaCO2 more than 55 mm Hg. For the group as a whole, PAP was mildly elevated with a mean value of 27.2 ± 8.9 mm Hg and a median value of 25 mm Hg. Sixty-five of 84 patients (77%) had pulmonary hypertension (PAP>20 mm Hg), PAP was 30 mm Hg or greater in 31 patients.
The cumulative survival rate for the group as a whole was 71% at 3 years and 48% at 5 years (Fig 1) . Actuarial survival curves were plotted for groups of patients subdivided according to the initial level of p<O.OOl) and when the cutoff value was 25 mm Hg (median value of PAP in our group) the results were similar (p<0.001). These results raise at least two questions: Why were pulmonary volumes and arterial blood gases of poor prognostic value? Why, on the other hand, did PAP appear as a good indicator of prognosis? First, it is important to underline that our series is well representative of COPD patients in whom 02 therapy is needed. The criteria for prescribing 02 were those commonly accepted (NOTT) and particular attention was paid to assess the stability of hypoxemia before initiating the treatment. 15 The mean initial PaO2 of our patients was identical to that of the patients included in both NOTT8 and MRC studies,9 and the mean PaCO2 was comparable to that of the NOTT patients.8 Furthermore, the overall 5-year survival rate of our 84 patients was 48%, which is rather similar to the life expectancy of the men receiving 02 for 15 h or more per day in the MRC study.9 In COPD patients given LTO, the 5-year survival rate varies, according to the series, from 30 to 62%.9,12,20-22 Thus, our figure of 48% agrees well with previous results obtained in patients with a comparable degree of severity.
We were surprised that the degree of airway obstruction and the level of hypoxemia and hyper capnia had no prognostic value in our series, which is different from the results of some earlier studies,12'20'21'23 but it does agree with results of others.13'22 Our finding could be explained by the fact who could include 217 patients, reported no difference in FEV1 between those who died and those who were still alive after 2 years. It, thus, appears that the discrepancies between the results reported in the literature cannot be satisfactorily explained by differences in the numbers of patients included. Another possible explanation is that some series of That age is a determinant factor of survival in patients with severe COPD receiving LTO or not is easy to understand and has been underlined in almost all series. 8, 14, 20, 23 In this regard, our results agree well with those of the medical literature. The prognostic value of PAP, in patients receiving LTO therapy, is more difficult to explain. Indeed, PAP is known to be a good indicator of prognosis in COPD patients not treated with 02 therapy,5-7 but this may not apply to patients receiving LTO therapy since this treatment allows the stabilization9 and sometimes the reversal'0"l of the progression of pulmonary hypertension. Cooper et a121 have noticed that LTO therapy "appears to interrupt the progression of hemodynamic disturbances ... and in doing so has deplaced the correlation of pulmonary hypertension with mortality." In our opinion, the level of PAP at the onset of 02 therapy is an overall index of the severity of the disease and can be considered as a marker of the deleterious effects of chronic hypoxia, which concern the pulmonary circulation but also other organs including the myocardium, the kidneys, and the brain. PAP could be a good indicator of prognosis even if LTO therapy allows the stabilization of pulmonary hypertension. Furthermore, most of the patients are not given 02 continuously, and some of them discontinue the treatment for several hours each day. We know from the study by Selinger et a125 that removing 02 in 2 to 3 h leads to a significant increase of PAP. The deleterious hemodynamic effects of removing 02 are probably more pronounced in those patients whose PAP is higher (>30 mm Hg). These patients are at a higher risk of harmful consequences of acute alveolar hypoxia: repetitive bouts of CHEST / 107 / 5/ MAY, 1995 1197 worsening of pulmonary hypertension could favor the development of right heart failure.
In conclusion, our study has shown that the level of PAP (together with age) is a good indicator of survival in COPD patients receiving LTO therapy. When PAP is moderately to markedly elevated (>30 mm Hg) at the onset of LTO therapy, the survival rate is decreased in comparison with patients with no or mild (<30 mm Hg) pulmonary hypertension. These results may suggest that LTO should be started earlier in hypoxemic COPD patients at a stage of mild (or even absent) pulmonary hypertension.
